It is noted in our most recent studies that SESN2‐dependent autophagy is required for anchorage‐independent growth inhibition by the anticancer compound isorhapontigenin (ISO) in human BC T24 and UMUC3 cells.23 Although we can't provide the exact mechanisms underlying the diversity effects of autophagy in mediation of anticancer and cancer development, we anticipate that there might be differential mechanisms that can control the divergent outcomes of BC cell growth or inhibition between SESN2‐dependent and ATG7‐dependent autophagy. This evidence concerns the gene SESN2 and cancer.